Antiphospholipid antibodies and the endothelium

Pier Luigi Meroni, Elena Raschi, Cinzia Testoni, Angela Tincani, Genesio Balestrieri

Research output: Contribution to journalArticle

Abstract

The interaction between aPL (particularly anti-β2GPI antibodies) and endothelium does represent a potential pathogenetic mechanism for the thrombotic manifestations of the syndrome. The autoantibody-mediated EC activation probably plays a role in sustaining the appearance of a proadhesive, proinflammatory, and procoagulant phenotype. The heterogeneity of the APS clinical manifestations is likely linked to the varied effects that aPL can induce on ECs and to the different functions that ECs display depending on the anatomic localization.

Original languageEnglish
Pages (from-to)587-602
Number of pages16
JournalRheumatic Disease Clinics of North America
Volume27
Issue number3
Publication statusPublished - 2001

Fingerprint

Antiphospholipid Antibodies
Autoantibodies
Endothelium
Anti-Idiotypic Antibodies
Phenotype

ASJC Scopus subject areas

  • Rheumatology

Cite this

Antiphospholipid antibodies and the endothelium. / Meroni, Pier Luigi; Raschi, Elena; Testoni, Cinzia; Tincani, Angela; Balestrieri, Genesio.

In: Rheumatic Disease Clinics of North America, Vol. 27, No. 3, 2001, p. 587-602.

Research output: Contribution to journalArticle

Meroni, PL, Raschi, E, Testoni, C, Tincani, A & Balestrieri, G 2001, 'Antiphospholipid antibodies and the endothelium', Rheumatic Disease Clinics of North America, vol. 27, no. 3, pp. 587-602.
Meroni, Pier Luigi ; Raschi, Elena ; Testoni, Cinzia ; Tincani, Angela ; Balestrieri, Genesio. / Antiphospholipid antibodies and the endothelium. In: Rheumatic Disease Clinics of North America. 2001 ; Vol. 27, No. 3. pp. 587-602.
@article{45b2ca67dbbc4265b7b612a8c15c1d82,
title = "Antiphospholipid antibodies and the endothelium",
abstract = "The interaction between aPL (particularly anti-β2GPI antibodies) and endothelium does represent a potential pathogenetic mechanism for the thrombotic manifestations of the syndrome. The autoantibody-mediated EC activation probably plays a role in sustaining the appearance of a proadhesive, proinflammatory, and procoagulant phenotype. The heterogeneity of the APS clinical manifestations is likely linked to the varied effects that aPL can induce on ECs and to the different functions that ECs display depending on the anatomic localization.",
author = "Meroni, {Pier Luigi} and Elena Raschi and Cinzia Testoni and Angela Tincani and Genesio Balestrieri",
year = "2001",
language = "English",
volume = "27",
pages = "587--602",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Antiphospholipid antibodies and the endothelium

AU - Meroni, Pier Luigi

AU - Raschi, Elena

AU - Testoni, Cinzia

AU - Tincani, Angela

AU - Balestrieri, Genesio

PY - 2001

Y1 - 2001

N2 - The interaction between aPL (particularly anti-β2GPI antibodies) and endothelium does represent a potential pathogenetic mechanism for the thrombotic manifestations of the syndrome. The autoantibody-mediated EC activation probably plays a role in sustaining the appearance of a proadhesive, proinflammatory, and procoagulant phenotype. The heterogeneity of the APS clinical manifestations is likely linked to the varied effects that aPL can induce on ECs and to the different functions that ECs display depending on the anatomic localization.

AB - The interaction between aPL (particularly anti-β2GPI antibodies) and endothelium does represent a potential pathogenetic mechanism for the thrombotic manifestations of the syndrome. The autoantibody-mediated EC activation probably plays a role in sustaining the appearance of a proadhesive, proinflammatory, and procoagulant phenotype. The heterogeneity of the APS clinical manifestations is likely linked to the varied effects that aPL can induce on ECs and to the different functions that ECs display depending on the anatomic localization.

UR - http://www.scopus.com/inward/record.url?scp=0034873886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034873886&partnerID=8YFLogxK

M3 - Article

C2 - 11534262

AN - SCOPUS:0034873886

VL - 27

SP - 587

EP - 602

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 3

ER -